🚀 VC round data is live in beta, check it out!
Viridian Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Viridian Therapeutics and similar public comparables like Vir Biotechnology, Square Pharma, MBX Biosciences, Zhejiang Jolly and more.
Viridian Therapeutics Overview
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Founded
2014
HQ
Employees
143
Website
Sectors
Financials (LTM)
EV
$880M
Viridian Therapeutics Financials
Viridian Therapeutics reported last 12-month revenue of $72M and negative EBITDA of ($363M).
In the same LTM period, Viridian Therapeutics generated $69M in gross profit, ($363M) in EBITDA losses, and had net loss of ($361M).
Revenue (LTM)
Viridian Therapeutics P&L
In the most recent fiscal year, Viridian Therapeutics reported revenue of $71M and EBITDA of ($334M).
Viridian Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $72M | XXX | $71M | XXX | XXX | XXX |
| Gross Profit | $69M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($363M) | XXX | ($334M) | XXX | XXX | XXX |
| EBITDA Margin | (507%) | XXX | (471%) | XXX | XXX | XXX |
| EBIT Margin | (533%) | XXX | (513%) | XXX | XXX | XXX |
| Net Profit | ($361M) | XXX | ($343M) | XXX | XXX | XXX |
| Net Margin | (505%) | XXX | (484%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Viridian Therapeutics Stock Performance
Viridian Therapeutics has current market cap of $2B, and enterprise value of $880M.
Market Cap Evolution
Viridian Therapeutics' stock price is $15.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $880M | $2B | 6.3% | XXX | XXX | XXX | $-3.35 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialViridian Therapeutics Valuation Multiples
Viridian Therapeutics trades at 12.3x EV/Revenue multiple, and (2.4x) EV/EBITDA.
EV / Revenue (LTM)
Viridian Therapeutics Financial Valuation Multiples
As of April 11, 2026, Viridian Therapeutics has market cap of $2B and EV of $880M.
Equity research analysts estimate Viridian Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Viridian Therapeutics has a P/E ratio of (4.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $880M | XXX | $880M | XXX | XXX | XXX |
| EV/Revenue | 12.3x | XXX | 12.4x | XXX | XXX | XXX |
| EV/EBITDA | (2.4x) | XXX | (2.6x) | XXX | XXX | XXX |
| EV/EBIT | (2.3x) | XXX | (2.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 12.7x | XXX | — | XXX | XXX | XXX |
| P/E | (4.4x) | XXX | (4.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Viridian Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Viridian Therapeutics Margins & Growth Rates
Viridian Therapeutics' revenue in the last 12 month grew by 84%.
Viridian Therapeutics' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $3.0M for the same period.
Viridian Therapeutics' rule of 40 is (595%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Viridian Therapeutics' rule of X is (589%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Viridian Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 84% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | (507%) | XXX | (471%) | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 32% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (595%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (589%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 147% | XXX | 135% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 479% | XXX | 478% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 613% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Viridian Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vir Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Square Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| MBX Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Jolly | XXX | XXX | XXX | XXX | XXX | XXX |
| Alembic Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Viridian Therapeutics M&A Activity
Viridian Therapeutics acquired XXX companies to date.
Last acquisition by Viridian Therapeutics was on XXXXXXXX, XXXXX. Viridian Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Viridian Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialViridian Therapeutics Investment Activity
Viridian Therapeutics invested in XXX companies to date.
Viridian Therapeutics made its latest investment on XXXXXXXX, XXXXX. Viridian Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Viridian Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Viridian Therapeutics
| When was Viridian Therapeutics founded? | Viridian Therapeutics was founded in 2014. |
| Where is Viridian Therapeutics headquartered? | Viridian Therapeutics is headquartered in United States. |
| How many employees does Viridian Therapeutics have? | As of today, Viridian Therapeutics has over 143 employees. |
| Who is the CEO of Viridian Therapeutics? | Viridian Therapeutics' CEO is Stephen Mahoney. |
| Is Viridian Therapeutics publicly listed? | Yes, Viridian Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Viridian Therapeutics? | Viridian Therapeutics trades under VRDN ticker. |
| When did Viridian Therapeutics go public? | Viridian Therapeutics went public in 2014. |
| Who are competitors of Viridian Therapeutics? | Viridian Therapeutics main competitors are Vir Biotechnology, Square Pharma, MBX Biosciences, Zhejiang Jolly. |
| What is the current market cap of Viridian Therapeutics? | Viridian Therapeutics' current market cap is $2B. |
| What is the current revenue of Viridian Therapeutics? | Viridian Therapeutics' last 12 months revenue is $72M. |
| What is the current revenue growth of Viridian Therapeutics? | Viridian Therapeutics revenue growth (NTM/LTM) is 84%. |
| What is the current EV/Revenue multiple of Viridian Therapeutics? | Current revenue multiple of Viridian Therapeutics is 12.3x. |
| Is Viridian Therapeutics profitable? | No, Viridian Therapeutics is not profitable. |
| What is the current EBITDA of Viridian Therapeutics? | Viridian Therapeutics has negative EBITDA and is not profitable. |
| What is Viridian Therapeutics' EBITDA margin? | Viridian Therapeutics' last 12 months EBITDA margin is (507%). |
| What is the current EV/EBITDA multiple of Viridian Therapeutics? | Current EBITDA multiple of Viridian Therapeutics is (2.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.